ArticleFrontiers in oncology2023

Next-generation sequencing identifies CDKN2A alterations as prognostic biomarkers in recurrent or metastatic head and neck squamous cell carcinoma predominantly receiving immune checkpoint inhibitors.

Liqiong Xue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.